Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celesio revenues, profits up
The company recorded group revenues of E15.9 billion for the period, including the acquired businesses of Danish pharmaceutical wholesalers K.V. Tjellesen and Max Jenne. EBITDA rose 8.6% to
The company recorded group revenues of E15.9 billion for the period, including the acquired businesses of Danish pharmaceutical wholesalers K.V. Tjellesen and Max Jenne. EBITDA rose 8.6% to
The deal has been implemented to improve the development of the drug Xolair a treatment for allergic asthma. Genentech and Tanox have been working together in collaboration with
The agreement combines both companies’ resources to enable complete project capabilities, ranging from technology development and component manufacturing to power plant construction and operation. Additionally, ACME will make
Patients were first treated with Provenge and then went on to receive docetaxel chemotherapy after disease progression. The analysis evaluated survival data from 82 patients who received docetaxel
The data demonstrated the safety, tolerability and predicted pharmacokinetics in low-dose cohorts from a phase I/II trial in patients with chronic lymphocytic leukemia and a phase I trial
Watson Pharmaceuticals, the recent acquirer of Andrx, is also being named in the lawsuits. The lawsuits result from an abbreviated new drug application filed by Andrx for generic
Naproxcinod is in phase III clinical development for the treatment of the signs and symptoms of osteoarthritis. Based on this current feedback and previous discussions held with the
Oxybutynin chloride extended release tablets are the generic version of Alza Corporation’s Ditropan XL. Ditropan XL had US sales of approximately $380 million during the 12-month period ended
Perrigo, who supplies the pain reliever to large US chain stores including Wal-Mart and Safeway, informed the Food and Drug Administration (FDA) that around one in 400,000 caplets
Orencia is for patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs such as methotrexate and TNF antagonists. The data also demonstrate that